Skip to Content

尊敬的客户：

目前国际形势复杂多变，关税政策尚不明朗，这可能对我们的产品价格产生一定影响。在此情况下，我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性，如果您选择在此期间下单，我们将保留根据实际情况调整价格的权利。同时，我们也理解市场变化可能给您带来的困扰，因此如果在订单实际发货前因关税政策变动导致价格出现较大波动，默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新，请点击此处查看详情。

Merck
CN
All Photos(1)

Key Documents

View All Documentation

A6226

Sigma-Aldrich

AM251

>98% (HPLC), solid, cannabinoid receptor (CB1) antagonist

Synonym(s):

1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide

Sign Into View Organizational & Contract Pricing

Select a Size

1 KG
CN¥1,202.23
5 KG
CN¥4,261.26

CN¥1,202.23

Estimated to ship onApril 28, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
1 KG
CN¥1,202.23
5 KG
CN¥4,261.26

About This Item

Empirical Formula (Hill Notation):
C22H21N4OCl2I
CAS Number:
183232-66-8
Molecular Weight:
555.24
MDL number:
MFCD01861181
UNSPSC Code:
12352200
PubChem Substance ID:
24891069
NACRES:
NA.77

CN¥1,202.23

Estimated to ship onApril 28, 2025Details

Request a Bulk Order

Product Name

AM251, >98% (HPLC), solid

Quality Level

100

Assay

>98% (HPLC)

form

solid

color

white

solubility

DMSO: >10 mg/mL
H2O: insoluble

originator

Sanofi Aventis

SMILES string

Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCCCC4

InChI

1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)

InChI key

BUZAJRPLUGXRAB-UHFFFAOYSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
193617193217A7330
乙酸铵 EMPLURA®

101115

乙酸铵

乙酸铵 EMPLURA®

193617

乙酸铵

乙酸铵 for analysis EMPARTA® ACS

193217

乙酸铵

乙酸铵 BioXtra, ≥98%

A7330

乙酸铵

assay

≥96.0% (alkalimetric)

assay

-

assay

-

assay

≥98%

solubility

1480 g/L

solubility

-

solubility

-

solubility

H2O: 1 M, clear, colorless

Quality Level

200

Quality Level

-

Quality Level

-

Quality Level

100

mp

114 °C

mp

-

mp

110-112 °C (dec.) (lit.)

mp

110-112 °C (dec.) (lit.)

density

1.17 g/cm3 at 20 °C

density

-

density

-

density

-

Application

AM251, a CB1 cannabinoid receptor antagonist, has been used in a study to determine its interaction with hippocampal neurons to enhance spatial memory in mice.

Biochem/physiol Actions

AM251 is a CB1 cannabinoid receptor antagonist.

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Salt content may vary.

Hazard Statements

H413

Precautionary Statements

P273 - P501

Hazard Classifications

Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves
  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    0000310720
    0000310720
    0000390807
    0000390809
    0000310714

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Nozomi Asaoka et al.
    The Journal of toxicological sciences, 41(6), 813-816 (2016-11-18)
    N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine methyl ester (5F-ADB) is one of the most potent synthetic cannabinoids and elicits severe psychotic symptoms in humans, sometimes causing death. To investigate the neuronal mechanisms underlying its toxicity, we examined the effects of 5F-ADB on midbrain dopaminergic and
    Elahe Mohammadi Vosough et al.
    Life sciences, 232, 116670-116670 (2019-07-23)
    Migraine is a neurological debilitating disorder. Previous studies have shown that cannabinoid receptor agonists have analgesic effects in various models of pain. In this study, therefore, we investigated anti-nociceptive effects of WIN 55,212-2, and the role of either CB1 or
    Ramy Khella et al.
    Psychopharmacology, 231(16), 3071-3087 (2014-04-08)
    Whilst cannabinoid CB2 receptors were thought to exist predominantly in immune cells in the periphery, the recent discovery of CB2 receptors in the brain has led to an increased interest in the role of these central CB2 receptors. Several studies
    Mahsa Shahidi et al.
    The Journal of general virology, 95(Pt 11), 2468-2479 (2014-07-24)
    Direct-acting antivirals have significantly improved treatment outcomes in chronic hepatitis C (CHC), but side effects, drug resistance and cost mean that better treatments are still needed. Lipid metabolism is closely linked with hepatitis C virus (HCV) replication, and endocannabinoids are
    Yuan Zong et al.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 43(5), 2088-2101 (2017-10-24)
    Cannabinoids are vasoactive substances that act as key regulators of arterial tone in the blood vessels supplying peripheral tissues and the central nervous system. We therefore investigated the effect of cannabinoids on retinal capillaries and pericytes. The effects of cannabinoids
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service